Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis.

ABSTRACT:

Background

The effects of disease-modifying therapies (DMTs) on region-specific brain atrophy in multiple sclerosis (MS) are unclear.

Objective

To determine the effects of higher versus lower efficacy DMTs on rates of brain substructure atrophy in MS.

Methods

A non-randomized, observational cohort of people with MS followed with annual brain magnetic resonance imaging (MRI) was evaluated retrospectively. Whole brain, subcortical gray matter (GM), cortical GM, and cerebral white matter (WM) volume fractions were obtained. DMTs were categorized as higher (DMT-H: natalizumab and rituximab) or lower (DMT-L: interferon-beta and glatiramer acetate) efficacy. Follow-up epochs were analyzed if participants had been on a DMT for ⩾6 months prior to baseline and had at least one

SUBMITTER: Sotirchos ES 

PROVIDER: S-EPMC6689465 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature